{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T19:01:03Z","timestamp":1793818863765,"version":"4.6.1"},"reference-count":294,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010029","name":"Taishan Scholar Foundation of Shandong Province","doi-asserted-by":"publisher","award":["tsqn202408138"],"award-info":[{"award-number":["tsqn202408138"]}],"id":[{"id":"10.13039\/501100010029","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32241014"],"award-info":[{"award-number":["32241014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32170687"],"award-info":[{"award-number":["32170687"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.pharmthera.2025.108934","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T23:24:16Z","timestamp":1759965856000},"page":"108934","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Crosstalk between anti-angiogenic and pro-angiogenic pathways in disease: Mechanisms and therapeutic strategies"],"prefix":"10.1016","volume":"276","author":[{"given":"Runa","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renshuai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb0005","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in patients with advanced and progressing hepatocellular carcinoma","volume":"379","author":"Abou-Alfa","year":"2018","journal-title":"The New England Journal of Medicine"},{"issue":"18","key":"10.1016\/j.pharmthera.2025.108934_bb0010","doi-asserted-by":"crossref","first-page":"8363","DOI":"10.1073\/pnas.0911378107","article-title":"Inhibition of mac-1 (CD11b\/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment","volume":"107","author":"Ahn","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108934_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/biom13111630","article-title":"Vitreous levels of vascular endothelial growth factor and platelet-derived growth factor in patients with proliferative diabetic retinopathy: A clinical correlation","volume":"13","author":"Al-Dwairi","year":"2023","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb0020","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12974-016-0657-9","article-title":"SPARC expression by cerebral microvascular endothelial cells in vitro and its influence on blood-brain barrier properties","volume":"13","author":"Alkabie","year":"2016","journal-title":"Journal of Neuroinflammation"},{"issue":"22","key":"10.1016\/j.pharmthera.2025.108934_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216288","article-title":"Blood-brain barrier breakdown in alzheimer\u2019s disease: Mechanisms and targeted strategies","volume":"24","author":"Alkhalifa","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb0030","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41419-017-0082-8","article-title":"Autophagy promotes MSC-mediated vascularization in cutaneous wound healing via regulation of VEGF secretion","volume":"9","author":"An","year":"2018","journal-title":"Cell Death & Disease"},{"issue":"16","key":"10.1016\/j.pharmthera.2025.108934_bb0035","doi-asserted-by":"crossref","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","article-title":"The tumor microenvironment","volume":"30","author":"Anderson","year":"2020","journal-title":"Current Biology"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108934_bb0040","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41574-020-00451-4","article-title":"Current understanding of the molecular and cellular pathology of diabetic retinopathy","volume":"17","author":"Antonetti","year":"2021","journal-title":"Nature Reviews. Endocrinology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb0045","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/APO.0000000000000570","article-title":"The role of inflammation in age-related macular degeneration: Updates and possible therapeutic approaches","volume":"12","author":"Arrigo","year":"2023","journal-title":"Asia Pacific Journal of Ophthalmology (Philadelphia)"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108934_bb0050","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/j.apmr.2020.05.005","article-title":"Differential effects of time to initiation of therapy on disability and quality of life in patients with mild and moderate to severe ischemic stroke","volume":"101","author":"Askew","year":"2020","journal-title":"Archives of Physical Medicine and Rehabilitation"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108934_bb0055","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1097\/IAE.0000000000001493","article-title":"Systemic pharmacokinetics and pharmacodynamics of intravitreal aflibercept, bevacizumab, and ranibizumab","volume":"37","author":"Avery","year":"2017","journal-title":"Retina"},{"issue":"50","key":"10.1016\/j.pharmthera.2025.108934_bb0060","article-title":"Pathologic vs. protective roles of hypoxia-inducible factor 1 in RPE and photoreceptors in wet vs. dry age-related macular degeneration","volume":"120","author":"Babapoor-Farrokhran","year":"2023","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb0065","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/s41392-024-02019-4","article-title":"EphrinB2-mediated CDK5\/ISL1 pathway enhances cardiac lymphangiogenesis and alleviates ischemic injury by resolving post-MI inflammation","volume":"9","author":"Bai","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb0070","doi-asserted-by":"crossref","first-page":"159","DOI":"10.5853\/jos.2019.02978","article-title":"Beyond the brain: The systemic pathophysiological response to acute ischemic stroke","volume":"22","author":"Balch","year":"2020","journal-title":"Journal of Stroke"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb0075","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1055\/s-0040-1713181","article-title":"Update in the treatment of retinopathy of prematurity","volume":"39","author":"Bancalari","year":"2022","journal-title":"American Journal of Perinatology"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108934_bb0080","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00401-009-0483-6","article-title":"Angiogenesis after cerebral ischemia","volume":"117","author":"Beck","year":"2009","journal-title":"Acta Neuropathologica"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108934_bb0085","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: The past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2025.108934_bb0090","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.3389\/fnins.2019.01452","article-title":"The neurovascular unit: Effects of brain insults during the perinatal period","volume":"13","author":"Bell","year":"2019","journal-title":"Frontiers in Neuroscience"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108934_bb0095","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/s41580-023-00682-z","article-title":"Patterning of the cell cortex by rho GTPases","volume":"25","author":"Bement","year":"2024","journal-title":"Nature Reviews. Molecular Cell Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb0100","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00018-024-05244-w","article-title":"Endothelial PDGF-D contributes to neurovascular protection after ischemic stroke by rescuing pericyte functions","volume":"81","author":"Bernard","year":"2024","journal-title":"Cellular and Molecular Life Sciences"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108934_bb0105","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","article-title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): A double-blind, randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Blay","year":"2020","journal-title":"The Lancet Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb0110","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/annonc\/mdx715","article-title":"Patients\u2019 preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: What makes it worthwhile?","volume":"29","author":"Blinman","year":"2018","journal-title":"Annals of Oncology"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108934_bb0115","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1089\/wound.2013.0496","article-title":"Anti-angiogenic drugs: Involvement in cutaneous side effects and wound-healing complication","volume":"3","author":"Bodnar","year":"2014","journal-title":"Advance Wound Care (New Rochelle)"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108934_bb0120","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1161\/CIRCRESAHA.121.318258","article-title":"Contemporary medical management of peripheral artery disease","volume":"128","author":"Bonaca","year":"2021","journal-title":"Circulation Research"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108934_bb0125","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1002\/eji.201747400","article-title":"Murine macrophage chemokine receptor CCR2 plays a crucial role in macrophage recruitment and regulated inflammation in wound healing","volume":"48","author":"Boniakowski","year":"2018","journal-title":"European Journal of Immunology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108934_bb0130","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1073\/pnas.1613855114","article-title":"Matrix stiffening promotes a tumor vasculature phenotype","volume":"114","author":"Bordeleau","year":"2017","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108934_bb0135","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41580-025-00835-2","article-title":"Modes of notch signalling in development and disease","volume":"26","author":"Bray","year":"2025","journal-title":"Nature Reviews. Molecular Cell Biology"},{"issue":"10064","key":"10.1016\/j.pharmthera.2025.108934_bb0140","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"Bruix","year":"2017","journal-title":"Lancet"},{"issue":"29","key":"10.1016\/j.pharmthera.2025.108934_bb0145","doi-asserted-by":"crossref","first-page":"3315","DOI":"10.1200\/JCO.2017.73.0226","article-title":"Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer: Results of a multicenter phase II international thyroid oncology group trial","volume":"35","author":"Cabanillas","year":"2017","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108934_bb0150","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00109-013-0993-5","article-title":"Ocular neovascularization","volume":"91","author":"Campochiaro","year":"2013","journal-title":"Journal of Molecular Medicine (Berlin, Germany)"},{"issue":"10436","key":"10.1016\/j.pharmthera.2025.108934_bb0155","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S0140-6736(24)00310-6","article-title":"Gene therapy for neovascular age-related macular degeneration by subretinal delivery of RGX-314: A phase 1\/2a dose-escalation study","volume":"403","author":"Campochiaro","year":"2024","journal-title":"Lancet"},{"issue":"5573","key":"10.1016\/j.pharmthera.2025.108934_bb0160","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1126\/science.296.5573.1655","article-title":"The phosphoinositide 3-kinase pathway","volume":"296","author":"Cantley","year":"2002","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb0165","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1038\/s41467-017-02373-8","article-title":"Polarized actin and VE-cadherin dynamics regulate junctional remodelling and cell migration during sprouting angiogenesis","volume":"8","author":"Cao","year":"2017","journal-title":"Nature Communications"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108934_bb0170","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/nm848","article-title":"Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2","volume":"9","author":"Cao","year":"2003","journal-title":"Nature Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108934_bb0175","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41573-023-00671-z","article-title":"Targeting angiogenesis in oncology, ophthalmology and beyond","volume":"22","author":"Cao","year":"2023","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108934_bb0180","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1158\/1078-0432.CCR-15-0600","article-title":"FDA approval summary: Ramucirumab for gastric cancer","volume":"21","author":"Casak","year":"2015","journal-title":"Clinical Cancer Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb0185","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41580-024-00777-1","article-title":"The role and regulation of integrins in cell migration and invasion","volume":"26","author":"Chastney","year":"2025","journal-title":"Nature Reviews. Molecular Cell Biology"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108934_bb0190","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1093\/brain\/awae156","article-title":"The vascular contribution of apolipoprotein E to Alzheimer's disease","volume":"147","author":"Chen","year":"2024","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb0195","first-page":"945","article-title":"Melatonin restricts the viability and angiogenesis of vascular endothelial cells by suppressing HIF-1alpha\/ROS\/VEGF","volume":"43","author":"Cheng","year":"2019","journal-title":"International Journal of Molecular Medicine"},{"issue":"10460","key":"10.1016\/j.pharmthera.2025.108934_bb0200","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S0140-6736(24)01758-6","article-title":"Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: Results of the phase 3 TiNivo-2 study","volume":"404","author":"Choueiri","year":"2024","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108934_bb0205","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.annonc.2020.04.010","article-title":"Updated efficacy results from the JAVELIN renal 101 trial: First-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma","volume":"31","author":"Choueiri","year":"2020","journal-title":"Annals of Oncology"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108934_bb0210","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"The New England Journal of Medicine"},{"issue":"33","key":"10.1016\/j.pharmthera.2025.108934_bb0215","doi-asserted-by":"crossref","first-page":"13444","DOI":"10.1073\/pnas.1110121108","article-title":"Injectable fibroblast growth factor-2 coacervate for persistent angiogenesis","volume":"108","author":"Chu","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2025.108934_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2019.109485","article-title":"Endothelial tight junctions and their regulatory signaling pathways in vascular homeostasis and disease","volume":"66","author":"Cong","year":"2020","journal-title":"Cellular Signalling"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108934_bb0225","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1177\/11206721221085870","article-title":"Long-term outcomes of anti-VEGF treatment of macular oedema due to retinal vein occlusions","volume":"32","author":"Corazza","year":"2022","journal-title":"European Journal of Ophthalmology"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108934_bb0230","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1111\/ceo.14225","article-title":"Management of macular oedema due to retinal vein occlusion: An evidence-based systematic review and meta-analysis","volume":"51","author":"Cornish","year":"2023","journal-title":"Clinical & Experimental Ophthalmology"},{"issue":"20","key":"10.1016\/j.pharmthera.2025.108934_bb0235","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1016\/j.cell.2022.09.004","article-title":"Ensembles of endothelial and mural cells promote angiogenesis in prenatal human brain","volume":"185","author":"Crouch","year":"2022","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108934_bb0240","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.yjmcc.2007.04.001","article-title":"HIF-1alpha induced-VEGF overexpression in bone marrow stem cells protects cardiomyocytes against ischemia","volume":"42","author":"Dai","year":"2007","journal-title":"Journal of Molecular and Cellular Cardiology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108934_bb0245","doi-asserted-by":"crossref","DOI":"10.1242\/dev.200472","article-title":"The beta8 integrin cytoplasmic domain activates extracellular matrix adhesion to promote brain neurovascular development","volume":"149","author":"De","year":"2022","journal-title":"Development"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108934_bb0250","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.cell.2015.12.056","article-title":"The cellular phase of Alzheimer's disease","volume":"164","author":"De Strooper","year":"2016","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108934_bb0255","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"The New England Journal of Medicine"},{"issue":"13","key":"10.1016\/j.pharmthera.2025.108934_bb0260","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Diabetic Retinopathy Clinical Research, N","year":"2015","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108934_bb0265","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1189\/jlb.4MR0316-102R","article-title":"Angiogenesis and wound repair: When enough is enough","volume":"100","author":"DiPietro","year":"2016","journal-title":"Journal of Leukocyte Biology"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108934_bb0270","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/NEN.0b013e31816a0dc8","article-title":"Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease","volume":"67","author":"Donahue","year":"2008","journal-title":"Journal of Neuropathology and Experimental Neurology"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108934_bb0275","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1177\/1535370215584939","article-title":"Adenosine A2B receptor stimulates angiogenesis by inducing VEGF and eNOS in human microvascular endothelial cells","volume":"240","author":"Du","year":"2015","journal-title":"Experimental Biology and Medicine (Maywood, N.J.)"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb0280","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb0285","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/CIRCRESAHA.120.316851","article-title":"Basic and therapeutic aspects of angiogenesis updated","volume":"127","author":"Eelen","year":"2020","journal-title":"Circulation Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108934_bb0290","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11892-019-1276-5","article-title":"Emerging concepts in the treatment of diabetic retinopathy","volume":"19","author":"Ellis","year":"2019","journal-title":"Current Diabetes Reports"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb0295","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"The New England Journal of Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb0300","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/annonc\/mdw561","article-title":"Sunitinib in pancreatic neuroendocrine tumors: Updated progression-free survival and final overall survival from a phase III randomized study","volume":"28","author":"Faivre","year":"2017","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.pharmthera.2025.108934_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.117018","article-title":"A gene-based anti-angiogenesis therapy as a novel strategy for cancer treatment","volume":"239","author":"Fallah","year":"2019","journal-title":"Life Sciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb0310","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12951-023-02066-z","article-title":"Enhanced therapeutic effect of PEDF-loaded mesenchymal stem cell-derived small extracellular vesicles against oxygen-induced retinopathy through increased stability and penetrability of PEDF","volume":"21","author":"Fan","year":"2023","journal-title":"Journal of Nanobiotechnology"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108934_bb0315","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41401-023-01061-2","article-title":"Angiogenesis after ischemic stroke","volume":"44","author":"Fang","year":"2023","journal-title":"Acta Pharmacologica Sinica"},{"key":"10.1016\/j.pharmthera.2025.108934_bb0320","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3389\/fnagi.2018.00077","article-title":"Recent advances: Decoding Alzheimer\u2019s disease with stem cells","volume":"10","author":"Fang","year":"2018","journal-title":"Frontiers in Aging Neuroscience"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108934_bb0325","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.tips.2023.03.003","article-title":"Targeted protein degrader development for cancer: Advances, challenges, and opportunities","volume":"44","author":"Fang","year":"2023","journal-title":"Trends in Pharmacological Sciences"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108934_bb0330","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nature Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108934_bb0335","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrd1381","article-title":"Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer","volume":"3","author":"Ferrara","year":"2004","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108934_bb0340","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.amjmed.2021.07.027","article-title":"Ischemic stroke","volume":"134","author":"Feske","year":"2021","journal-title":"The American Journal of Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb0345","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jama.2023.26074","article-title":"Age-related macular degeneration: A review","volume":"331","author":"Fleckenstein","year":"2024","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108934_bb0350","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12051055","article-title":"Vascular endothelial growth factor (VEGF) and its role in the cardiovascular system","volume":"12","author":"Florek","year":"2024","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108934_bb0355","first-page":"CD012058","article-title":"Gene therapy for peripheral arterial disease","volume":"10","author":"Forster","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"14","key":"10.1016\/j.pharmthera.2025.108934_bb0360","doi-asserted-by":"crossref","first-page":"19048","DOI":"10.18632\/aging.203354","article-title":"Combined treatment with C16 peptide and angiopoietin-1 confers neuroprotection and reduces inflammation in 3-nitropropionic acid-induced dystonia mice","volume":"13","author":"Fu","year":"2021","journal-title":"Aging (Albany NY)"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108934_bb0365","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00395-006-0629-9","article-title":"Intravenous injection of phagocytes transfected ex vivo with FGF4 DNA\/biodegradable gelatin complex promotes angiogenesis in a rat myocardial ischemia\/reperfusion injury model","volume":"102","author":"Fukuyama","year":"2007","journal-title":"Basic Research in Cardiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb0370","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1124\/pharmrev.121.000418","article-title":"Therapeutic opportunities and delivery strategies for brain revascularization in stroke, neurodegeneration, and aging","volume":"74","author":"Gallego","year":"2022","journal-title":"Pharmacological Reviews"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb0375","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1161\/CIRCULATIONAHA.118.034165","article-title":"Antiangiogenic VEGF(165)b regulates macrophage polarization via S100A8\/S100A9 in peripheral artery disease","volume":"139","author":"Ganta","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb0380","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCRESAHA.116.309516","article-title":"VEGF165b modulates endothelial VEGFR1-STAT3 signaling pathway and angiogenesis in human and experimental peripheral arterial disease","volume":"120","author":"Ganta","year":"2017","journal-title":"Circulation Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108934_bb0385","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.7150\/thno.40595","article-title":"Coronary artery mechanics induces human saphenous vein remodelling via recruitment of adventitial myofibroblast-like cells mediated by Thrombospondin-1","volume":"10","author":"Garoffolo","year":"2020","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb0390","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s42003-020-01606-9","article-title":"BMP-2 and VEGF-A modRNAs in collagen scaffold synergistically drive bone repair through osteogenic and angiogenic pathways","volume":"4","author":"Geng","year":"2021","journal-title":"Communications Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb0395","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s12964-019-0340-8","article-title":"Targeting pericytes for neurovascular regeneration","volume":"17","author":"Geranmayeh","year":"2019","journal-title":"Cell Communication and Signaling: CCS"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108934_bb0400","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1083\/jcb.200302047","article-title":"VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia","volume":"161","author":"Gerhardt","year":"2003","journal-title":"The Journal of Cell Biology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb0405","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1152\/physrev.00005.2020","article-title":"The FGF\/FGFR system in the physiopathology of the prostate gland","volume":"101","author":"Giacomini","year":"2021","journal-title":"Physiological Reviews"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108934_bb0410","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/sctm.19-0319","article-title":"Therapeutic vascularization in regenerative medicine","volume":"9","author":"Gianni-Barrera","year":"2020","journal-title":"Stem Cells Translational Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108934_bb0415","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/nm0596-534","article-title":"Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart","volume":"2","author":"Giordano","year":"1996","journal-title":"Nature Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb0420","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1038\/s41467-023-38563-w","article-title":"Antibody blockade of Jagged1 attenuates choroidal neovascularization","volume":"14","author":"Gjolberg","year":"2023","journal-title":"Nature Communications"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108934_bb0425","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.ophtha.2020.03.021","article-title":"Five-year outcomes after initial aflibercept, bevacizumab, or ranibizumab treatment for diabetic macular edema (protocol T extension study)","volume":"127","author":"Glassman","year":"2020","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108934_bb0430","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1002\/jcp.29412","article-title":"Wortmannin targeting phosphatidylinositol 3-kinase suppresses angiogenic factors in shear-stressed endothelial cells","volume":"235","author":"Gomes","year":"2020","journal-title":"Journal of Cellular Physiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb0435","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jid.2024.05.027","article-title":"Fetal skin wound healing: Key extracellular matrix components and regulators in scarless healing","volume":"145","author":"Gomes","year":"2025","journal-title":"The Journal of Investigative Dermatology"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108934_bb0440","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.1161\/STR.0b013e3182299496","article-title":"Vascular contributions to cognitive impairment and dementia: A statement for healthcare professionals from the american heart association\/american stroke association","volume":"42","author":"Gorelick","year":"2011","journal-title":"Stroke"},{"issue":"24","key":"10.1016\/j.pharmthera.2025.108934_bb0445","doi-asserted-by":"crossref","first-page":"e1313","DOI":"10.1161\/CIR.0000000000001251","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease: A report of the american college of cardiology\/american heart association joint committee on clinical practice guidelines","volume":"149","author":"Gornik","year":"2024","journal-title":"Circulation"},{"issue":"27","key":"10.1016\/j.pharmthera.2025.108934_bb0450","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1056\/NEJMoa042760","article-title":"Pegaptanib for neovascular age-related macular degeneration","volume":"351","author":"Gragoudas","year":"2004","journal-title":"The New England Journal of Medicine"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108934_bb0455","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1089\/wound.2021.0038","article-title":"Understanding scarring in the oral mucosa","volume":"11","author":"Griffin","year":"2022","journal-title":"Advance Wound Care (New Rochelle)"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb0460","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ymthe.2018.11.003","article-title":"Preclinical evaluation of ADVM-022, a novel gene therapy approach to treating wet age-related macular degeneration","volume":"27","author":"Grishanin","year":"2019","journal-title":"Molecular Therapy"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108934_bb0465","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201745054","article-title":"EphrinB2\/EphB4 signaling regulates non-sprouting angiogenesis by VEGF","volume":"19","author":"Groppa","year":"2018","journal-title":"EMBO Reports"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108934_bb0470","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1001\/jamaophthalmol.2018.3255","article-title":"Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial","volume":"136","author":"Gross","year":"2018","journal-title":"JAMA Ophthalmology"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108934_bb0475","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s10456-021-09791-9","article-title":"Notch regulates vascular collagen IV basement membrane through modulation of lysyl hydroxylase 3 trafficking","volume":"24","author":"Gross","year":"2021","journal-title":"Angiogenesis"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108934_bb0480","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41568-024-00736-0","article-title":"Targeting the tumour vasculature: From vessel destruction to promotion","volume":"24","author":"Guelfi","year":"2024","journal-title":"Nature Reviews. Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb0485","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/2045-824X-5-20","article-title":"The role of tumor-associated macrophages in tumor vascularization","volume":"5","author":"Guo","year":"2013","journal-title":"Vascular Cell"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb0490","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1006\/excr.1998.4359","article-title":"VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK\/ERK and SAPK\/JNK signaling","volume":"247","author":"Gupta","year":"1999","journal-title":"Experimental Cell Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108934_bb0495","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.ophtha.2018.09.015","article-title":"Subthreshold nanosecond laser intervention in age-related macular degeneration: The LEAD randomized controlled clinical trial","volume":"126","author":"Guymer","year":"2019","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108934_bb0500","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.apsb.2020.11.023","article-title":"Evolution of blood-brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies","volume":"11","author":"Han","year":"2021","journal-title":"Acta Pharmaceutica Sinica B"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108934_bb0505","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.7150\/thno.50928","article-title":"Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes","volume":"11","author":"Han","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.pharmthera.2025.108934_bb0510","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ajo.2020.05.025","article-title":"Retinopathy of prematurity: Evolving treatment with anti-vascular endothelial growth factor","volume":"218","author":"Hartnett","year":"2020","journal-title":"American Journal of Ophthalmology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb0515","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4103\/1673-5374.264442","article-title":"Angiogenesis and neuronal remodeling after ischemic stroke","volume":"15","author":"Hatakeyama","year":"2020","journal-title":"Neural Regeneration Research"},{"issue":"13","key":"10.1016\/j.pharmthera.2025.108934_bb0520","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1016\/j.ejca.2008.06.031","article-title":"VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis","volume":"44","author":"Hawinkels","year":"2008","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2025.108934_bb0525","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.100964","article-title":"Photocoagulation for retinal vein occlusion","volume":"85","author":"Hayreh","year":"2021","journal-title":"Progress in Retinal and Eye Research"},{"key":"10.1016\/j.pharmthera.2025.108934_bb0530","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.801985","article-title":"Biological functions and regulatory mechanisms of hypoxia-inducible factor-1alpha in ischemic stroke","volume":"12","author":"He","year":"2021","journal-title":"Frontiers in Immunology"},{"issue":"21","key":"10.1016\/j.pharmthera.2025.108934_bb0535","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1161\/01.CIR.0000070540.80780.92","volume":"107","author":"Hedman","year":"2003","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108934_bb0540","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"issue":"10411","key":"10.1016\/j.pharmthera.2025.108934_bb0545","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/S0140-6736(23)01520-9","article-title":"Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): Two multicentre, randomised, double-masked, sham-controlled, phase 3 trials","volume":"402","author":"Heier","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2025.108934_bb0550","first-page":"2677","article-title":"Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson\u2019s disease","volume":"9","author":"Herran","year":"2014","journal-title":"International Journal of Nanomedicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108934_bb0555","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.clp.2019.05.008","article-title":"Oxygen saturation and retinopathy of prematurity","volume":"46","author":"Higgins","year":"2019","journal-title":"Clinics in Perinatology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108934_bb0560","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.ophtha.2021.09.016","article-title":"Archway randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration","volume":"129","author":"Holekamp","year":"2022","journal-title":"Ophthalmology"},{"key":"10.1016\/j.pharmthera.2025.108934_bb0565","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41421-017-0002-1","article-title":"Dual roles of endothelial FGF-2-FGFR1-PDGF-BB and perivascular FGF-2-FGFR2-PDGFRbeta signaling pathways in tumor vascular remodeling","volume":"4","author":"Hosaka","year":"2018","journal-title":"Cell Discovery"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108934_bb0570","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s11357-019-00118-7","article-title":"Transforming growth factor-beta promotes basement membrane fibrosis, alters perivascular cerebrospinal fluid distribution, and worsens neurological recovery in the aged brain after stroke","volume":"41","author":"Howe","year":"2019","journal-title":"Geroscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb0575","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s10384-023-01034-2","article-title":"Vitreomacular traction in diabetic retinopathy","volume":"68","author":"Hsieh","year":"2024","journal-title":"Japanese Journal of Ophthalmology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108934_bb0580","doi-asserted-by":"crossref","first-page":"647","DOI":"10.14336\/AD.2021.1121","article-title":"VEGF, a key factor for blood brain barrier injury after cerebral ischemic stroke","volume":"13","author":"Hu","year":"2022","journal-title":"Aging and Disease"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108934_bb0585","first-page":"8369","article-title":"Anti-angiogenesis or pro-angiogenesis for cancer treatment: Focus on drug distribution","volume":"8","author":"Huang","year":"2015","journal-title":"International Journal of Clinical and Experimental Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108934_bb0590","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00417-021-05224-x","article-title":"Disease-modifying effects of ranibizumab for central retinal vein occlusion","volume":"260","author":"Huang","year":"2022","journal-title":"Graefe\u2019s Archive for Clinical and Experimental Ophthalmology"},{"issue":"13","key":"10.1016\/j.pharmthera.2025.108934_bb0595","article-title":"A nucleic acid-based LYTAC plus platform to simultaneously mediate disease-driven protein downregulation","volume":"11","author":"Huang","year":"2024","journal-title":"Advance Science (Weinh)"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108934_bb0600","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1089\/thy.2018.0784","article-title":"Body composition in patients with radioactive iodine-refractory, advanced differentiated thyroid cancer treated with sorafenib or placebo: A retrospective analysis of the phase III DECISION trial","volume":"29","author":"Huillard","year":"2019","journal-title":"Thyroid"},{"issue":"23","key":"10.1016\/j.pharmthera.2025.108934_bb0605","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"The New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108934_bb0610","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrm3908","article-title":"Stretching the boundaries of extracellular matrix research","volume":"15","author":"Hynes","year":"2014","journal-title":"Nature Reviews. Molecular Cell Biology"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108934_bb0615","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1474-4422(22)00165-X","article-title":"Moyamoya disease: diagnosis and interventions","volume":"21","author":"Ihara","year":"2022","journal-title":"Lancet Neurology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb0620","first-page":"40","article-title":"Retinal vein occlusion review","volume":"7","author":"Ip","year":"2018","journal-title":"Asia Pacific Journal of Ophthalmology (Philadelphia)"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108934_bb0625","doi-asserted-by":"crossref","first-page":"6349","DOI":"10.1074\/jbc.M114.634154","article-title":"Insulin-like growth factor 1 (IGF-1) stabilizes nascent blood vessels","volume":"290","author":"Jacobo","year":"2015","journal-title":"The Journal of Biological Chemistry"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108934_bb0630","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ophtha.2020.08.027","article-title":"C5 inhibitor avacincaptad pegol for geographic atrophy due to age-related macular degeneration: A randomized pivotal phase 2\/3 trial","volume":"128","author":"Jaffe","year":"2021","journal-title":"Ophthalmology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb0635","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.stem.2021.10.009","article-title":"Hif-1a suppresses ROS-induced proliferation of cardiac fibroblasts following myocardial infarction","volume":"29","author":"Janbandhu","year":"2022","journal-title":"Cell Stem Cell"},{"issue":"13","key":"10.1016\/j.pharmthera.2025.108934_bb0640","doi-asserted-by":"crossref","first-page":"8246","DOI":"10.1167\/iovs.12-10918","article-title":"Topographical distribution of retinal and optic disc neovascularization in early stages of proliferative diabetic retinopathy","volume":"53","author":"Jansson","year":"2012","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1016\/j.pharmthera.2025.108934_bb0645","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.expneurol.2014.05.013","article-title":"Angiopoietin-1 ameliorates inflammation-induced vascular leakage and improves functional impairment in a rat model of acute experimental autoimmune encephalomyelitis","volume":"261","author":"Jiang","year":"2014","journal-title":"Experimental Neurology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb0650","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/s12915-023-01792-y","article-title":"Biomechanical stimulation promotes blood vessel growth despite VEGFR-2 inhibition","volume":"21","author":"Johnson","year":"2023","journal-title":"BMC Biology"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108934_bb0655","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1089\/wound.2013.0517","article-title":"Vascular endothelial growth factor and angiogenesis in the regulation of cutaneous wound repair","volume":"3","author":"Johnson","year":"2014","journal-title":"Advance Wound Care (New Rochelle)"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb0660","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s00109-018-1729-3","article-title":"Approaches to therapeutic angiogenesis for ischemic heart disease","volume":"97","author":"Johnson","year":"2019","journal-title":"Journal of Molecular Medicine (Berlin, Germany)"},{"issue":"28","key":"10.1016\/j.pharmthera.2025.108934_bb0665","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.21.00217","article-title":"Avapritinib versus regorafenib in locally advanced unresectable or metastatic GI stromal tumor: A randomized, open-label phase III study","volume":"39","author":"Kang","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108934_bb0670","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0288805","article-title":"Functional and structural outcomes and complications after pars plana vitrectomy for severe features of proliferative diabetic retinopathy in type 1 and type 2 diabetes mellitus","volume":"18","author":"Kazmierczak","year":"2023","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108934_bb0675","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan","year":"2018","journal-title":"Nature Reviews. Clinical Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb0680","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3858\/emm.2012.44.1.023","article-title":"Role of placenta growth factor in cancer and inflammation","volume":"44","author":"Kim","year":"2012","journal-title":"Experimental & Molecular Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb0685","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.ajpath.2012.06.006","article-title":"A brief history of anti-VEGF for the treatment of ocular angiogenesis","volume":"181","author":"Kim","year":"2012","journal-title":"The American Journal of Pathology"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108934_bb0690","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1172\/JCI84871","article-title":"Opposing actions of angiopoietin-2 on Tie2 signaling and FOXO1 activation","volume":"126","author":"Kim","year":"2016","journal-title":"The Journal of Clinical Investigation"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb0695","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1634\/theoncologist.2018-0464","article-title":"A phase II trial of pazopanib in patients with metastatic alveolar soft part sarcoma","volume":"24","author":"Kim","year":"2019","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108934_bb0700","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nrn.2017.48","article-title":"Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease","volume":"18","author":"Kisler","year":"2017","journal-title":"Nature Reviews. Neuroscience"},{"key":"10.1016\/j.pharmthera.2025.108934_bb0705","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ebiom.2018.04.021","article-title":"The novel pathogenesis of retinopathy mediated by multiple RTK signals is uncovered in newly developed mouse model","volume":"31","author":"Kitahara","year":"2018","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108934_bb0710","doi-asserted-by":"crossref","first-page":"429","DOI":"10.5551\/jat.64457","article-title":"Evaluating total atherosclerosis burden of baroreceptor-resident arteries after ischemic cerebrovascular disease for identifying patients with heavy coronary atherosclerosis burden","volume":"31","author":"Kong","year":"2024","journal-title":"Journal of Atherosclerosis and Thrombosis"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108934_bb0715","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1172\/JCI84923","article-title":"Tie1 controls angiopoietin function in vascular remodeling and inflammation","volume":"126","author":"Korhonen","year":"2016","journal-title":"The Journal of Clinical Investigation"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108934_bb0720","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1161\/01.STR.25.9.1794","article-title":"Role of angiogenesis in patients with cerebral ischemic stroke","volume":"25","author":"Krupinski","year":"1994","journal-title":"Stroke"},{"issue":"10126","key":"10.1016\/j.pharmthera.2025.108934_bb0725","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"issue":"17","key":"10.1016\/j.pharmthera.2025.108934_bb0730","doi-asserted-by":"crossref","DOI":"10.3390\/cells11172676","article-title":"Targeting anti-angiogenic VEGF(165)b-VEGFR1 signaling promotes nitric oxide independent therapeutic angiogenesis in preclinical peripheral artery disease models","volume":"11","author":"Kuppuswamy","year":"2022","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108934_bb0735","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jamaophthalmol.2023.1463","article-title":"Cost-utility comparison of bevacizumab and aflibercept in the treatment of central or hemiretinal vein occlusion in the SCORE2 trial","volume":"141","author":"Kymes","year":"2023","journal-title":"JAMA Ophthalmology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108934_bb0740","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s00280-018-3579-7","article-title":"Population exposure-response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma","volume":"81","author":"Lacy","year":"2018","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108934_bb0745","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/01.RES.0000259593.07661.1e","article-title":"Endothelial cell migration during angiogenesis","volume":"100","author":"Lamalice","year":"2007","journal-title":"Circulation Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108934_bb0750","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1001\/jamaneurol.2023.3344","article-title":"Underlying causes of TIA and minor ischemic stroke and risk of major vascular events","volume":"80","author":"Lavallee","year":"2023","journal-title":"JAMA Neurology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb0755","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41392-025-02249-0","article-title":"Vascular endothelial growth factor signaling in health and disease: From molecular mechanisms to therapeutic perspectives","volume":"10","author":"Lee","year":"2025","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"16","key":"10.1016\/j.pharmthera.2025.108934_bb0760","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1161\/CIRCULATIONAHA.121.054071","article-title":"Role of venous endothelial cells in developmental and pathologic angiogenesis","volume":"144","author":"Lee","year":"2021","journal-title":"Circulation"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb0765","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1038\/s41467-020-18031-5","article-title":"In vitro generation of functional murine heart organoids via FGF4 and extracellular matrix","volume":"11","author":"Lee","year":"2020","journal-title":"Nature Communications"},{"issue":"4935","key":"10.1016\/j.pharmthera.2025.108934_bb0770","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.2479986","article-title":"Vascular endothelial growth factor is a secreted angiogenic mitogen","volume":"246","author":"Leung","year":"1989","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb0775","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1080\/13880209.2021.2013259","article-title":"Concanavalin A promotes angiogenesis and proliferation in endothelial cells through the Akt\/ERK\/cyclin D1 axis","volume":"60","author":"Li","year":"2022","journal-title":"Pharmaceutical Biology"},{"issue":"31","key":"10.1016\/j.pharmthera.2025.108934_bb0780","first-page":"2895","article-title":"Hypoxic preconditioning stimulates angiogenesis in ischemic penumbra after acute cerebral infarction","volume":"8","author":"Li","year":"2013","journal-title":"Neural Regeneration Research"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108934_bb0785","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41569-023-00886-y","article-title":"Interplay of hypoxia-inducible factors and oxygen therapy in cardiovascular medicine","volume":"20","author":"Liang","year":"2023","journal-title":"Nature Reviews. Cardiology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108934_bb0790","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1148\/radiol.2015150319","article-title":"Whole-brain CT perfusion to quantify acute ischemic penumbra and core","volume":"279","author":"Lin","year":"2016","journal-title":"Radiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb0795","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1111\/jcmm.14904","article-title":"NFAT5 promotes arteriogenesis via MCP-1-dependent monocyte recruitment","volume":"24","author":"Lin","year":"2020","journal-title":"Journal of Cellular and Molecular Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108934_bb0800","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1167\/iovs.64.7.11","article-title":"Associations of VEGF polymorphisms with retinopathy of prematurity","volume":"64","author":"Ling","year":"2023","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"10.1016\/j.pharmthera.2025.108934_bb0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113941","article-title":"Coptisine protects against hyperuricemic nephropathy through alleviating inflammation, oxidative stress and mitochondrial apoptosis via PI3K\/Akt signaling pathway","volume":"156","author":"Liu","year":"2022","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb0810","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108934_bb0815","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"The New England Journal of Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108934_bb0820","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1242\/dev.072348","article-title":"Diverse roles for VEGF-A in the nervous system","volume":"139","author":"Mackenzie","year":"2012","journal-title":"Development"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108934_bb0825","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.ophtha.2016.03.045","article-title":"Five-year outcomes with anti-vascular endothelial growth factor treatment of Neovascular age-related macular degeneration: The comparison of age-related macular degeneration treatments trials","volume":"123","author":"Maguire","year":"2016","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108934_bb0830","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110309","article-title":"Macrophage IL-1beta promotes arteriogenesis by autocrine STAT3- and NF-kappaB-mediated transcription of pro-angiogenic VEGF-A","volume":"38","author":"Mantsounga","year":"2022","journal-title":"Cell Reports"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108934_bb0835","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1001\/jama.2020.26867","article-title":"Diagnosis and management of transient ischemic attack and acute ischemic stroke: A review","volume":"325","author":"Mendelson","year":"2021","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.pharmthera.2025.108934_bb0840","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1007\/s00018-014-1678-0","article-title":"Mechanisms of endothelial cell migration","volume":"71","author":"Michaelis","year":"2014","journal-title":"Cellular and Molecular Life Sciences"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108934_bb0845","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMoa1007374","article-title":"Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity","volume":"364","author":"Mintz-Hittner","year":"2011","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108934_bb0850","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1136\/bjophthalmol-2020-316214","article-title":"Changes in choroidal structure following intravitreal aflibercept therapy for retinal vein occlusion","volume":"105","author":"Mitamura","year":"2021","journal-title":"The British Journal of Ophthalmology"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108934_bb0855","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1084\/jem.20132130","article-title":"Chemokine-coupled beta2 integrin-induced macrophage Rac2-myosin IIA interaction regulates VEGF-A mRNA stability and arteriogenesis","volume":"211","author":"Morrison","year":"2014","journal-title":"The Journal of Experimental Medicine"},{"issue":"15","key":"10.1016\/j.pharmthera.2025.108934_bb0860","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: A randomised, phase 2, open-label, multicentre trial","volume":"16","author":"Motzer","year":"2015","journal-title":"The Lancet Oncology"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb0865","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamaoncol.2021.5981","article-title":"Final overall survival and molecular analysis in immotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously untreated metastatic renal cell carcinoma","volume":"8","author":"Motzer","year":"2022","journal-title":"JAMA Oncology"},{"issue":"21","key":"10.1016\/j.pharmthera.2025.108934_bb0870","article-title":"Deficiency of notch signaling in pericytes results in arteriovenous malformations. JCI","volume":"5","author":"Nadeem","year":"2020","journal-title":"Insight"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb0875","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12974-023-02918-3","article-title":"CD13 facilitates immune cell migration and aggravates acute injury but promotes chronic post-stroke recovery","volume":"20","author":"Nguyen","year":"2023","journal-title":"Journal of Neuroinflammation"},{"key":"10.1016\/j.pharmthera.2025.108934_bb0880","article-title":"Efficacy and safety of intravitreal faricimab in neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion: A meta-analysis","volume":"1-18","author":"Nichani","year":"2024","journal-title":"Ophthalmologica"},{"key":"10.1016\/j.pharmthera.2025.108934_bb0885","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.117080","article-title":"Angiopoietin 2 signal complexity in cardiovascular disease and cancer","volume":"239","author":"Nicolini","year":"2019","journal-title":"Life Sciences"},{"issue":"10421","key":"10.1016\/j.pharmthera.2025.108934_bb0890","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(23)02405-4","article-title":"Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): A randomised, open-label, phase 3 trial","volume":"403","author":"Oaknin","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb0895","doi-asserted-by":"crossref","first-page":"34","DOI":"10.5847\/wjem.j.1920-8642.2017.01.006","article-title":"Comparison of neurological clinical manifestation in patients with hemorrhagic and ischemic stroke","volume":"8","author":"Ojaghihaghighi","year":"2017","journal-title":"World Journal of Emergency Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108934_bb0900","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9050524","article-title":"Neuroinflammation in Alzheimer\u2019s disease","volume":"9","author":"Onyango","year":"2021","journal-title":"Biomedicines"},{"issue":"10397","key":"10.1016\/j.pharmthera.2025.108934_bb0905","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0140-6736(23)00922-4","article-title":"Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): A multicentre, randomised, open-label, phase 3 trial","volume":"402","author":"Pal","year":"2023","journal-title":"Lancet"},{"issue":"8024","key":"10.1016\/j.pharmthera.2025.108934_bb0910","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-024-07698-1","article-title":"Tumour vasculature at single-cell resolution","volume":"632","author":"Pan","year":"2024","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108934_bb0915","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2018.11.029","article-title":"Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial","volume":"70","author":"Park","year":"2019","journal-title":"Journal of Hepatology"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108934_bb0920","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1200\/JCO.23.01891","article-title":"Phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated non-small-cell lung cancer (ATTLAS, KCSG-LU19-04)","volume":"42","author":"Park","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108934_bb0925","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.molcel.2008.04.008","article-title":"Comprehensive identification of PIP3-regulated PH domains from C. elegans to H. sapiens by model prediction and live imaging","volume":"30","author":"Park","year":"2008","journal-title":"Molecular Cell"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108934_bb0930","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19041264","article-title":"Molecular pharmacology of VEGF-A isoforms: Binding and signalling at VEGFR2","volume":"19","author":"Peach","year":"2018","journal-title":"International Journal of Molecular Sciences"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108934_bb0935","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/s41580-024-00715-1","article-title":"Cellular and molecular mechanisms of skin wound healing","volume":"25","author":"Pe\u00f1a","year":"2024","journal-title":"Nature Reviews. Molecular Cell Biology"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108934_bb0940","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41580-023-00631-w","article-title":"Biology and therapeutic targeting of vascular endothelial growth factor A","volume":"24","author":"P\u00e9rez-Guti\u00e9rrez","year":"2023","journal-title":"Nature Reviews. Molecular Cell Biology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108934_bb0945","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/S1470-2045(19)30827-7","article-title":"TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: An investigator-initiated, open-label, randomised, phase 2 trial","volume":"21","author":"Pfeiffer","year":"2020","journal-title":"The Lancet Oncology"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108934_bb0950","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S1470-2045(20)30142-X","article-title":"Bevacizumab and platinum-based combinations for recurrent ovarian cancer: A randomised, open-label, phase 3 trial","volume":"21","author":"Pfisterer","year":"2020","journal-title":"The Lancet Oncology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108934_bb0955","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1073\/pnas.92.3.905","article-title":"Vascular endothelial growth factor\/vascular permeability factor expression in a mouse model of retinal neovascularization","volume":"92","author":"Pierce","year":"1995","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108934_bb0960","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/jop.2023.0105","article-title":"Intravitreal dexamethasone as a rescue for anti-vascular endothelial growth factor therapy in neovascular age-related macular degeneration with persistent disease activity and high treatment demand","volume":"40","author":"Pietzuch","year":"2024","journal-title":"Journal of Ocular Pharmacology and Therapeutics"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108934_bb0965","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/ncb3555","article-title":"Dll4 and notch signalling couples sprouting angiogenesis and artery formation","volume":"19","author":"Pitulescu","year":"2017","journal-title":"Nature Cell Biology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108934_bb0970","doi-asserted-by":"crossref","DOI":"10.3390\/cells10030687","article-title":"Cell-matrix interactions in the eye: From cornea to choroid","volume":"10","author":"Pouw","year":"2021","journal-title":"Cells"},{"issue":"18","key":"10.1016\/j.pharmthera.2025.108934_bb0975","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"The New England Journal of Medicine"},{"issue":"10","key":"10.1016\/j.pharmthera.2025.108934_bb0980","doi-asserted-by":"crossref","first-page":"4374","DOI":"10.1038\/s41380-023-02097-w","article-title":"VEGF-A in serum protects against memory impairment in APP\/PS1 transgenic mice by blocking neutrophil infiltration","volume":"28","author":"Qi","year":"2023","journal-title":"Molecular Psychiatry"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb0985","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41392-022-01064-1","article-title":"Signaling pathways involved in ischemic stroke: Molecular mechanisms and therapeutic interventions","volume":"7","author":"Qin","year":"2022","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"13","key":"10.1016\/j.pharmthera.2025.108934_bb0990","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.96002","article-title":"Tie2 regulates endocardial sprouting and myocardial trabeculation","volume":"5","author":"Qu","year":"2019","journal-title":"JCI Insight"},{"issue":"16","key":"10.1016\/j.pharmthera.2025.108934_bb0995","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/01.CIR.0000093398.16124.29","volume":"108","author":"Rajagopalan","year":"2003","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb1000","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.bbrc.2013.11.090","article-title":"Fibronectin alters the rate of formation and structure of the fibrin matrix","volume":"443","author":"Ramanathan","year":"2014","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"21","key":"10.1016\/j.pharmthera.2025.108934_bb1005","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1200\/JCO.22.00912","article-title":"Phase II randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small-cell lung cancer previously treated with immunotherapy-lung-MAP S1800A","volume":"40","author":"Reckamp","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108934_bb1010","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ophtha.2023.02.024","article-title":"Archway Phase 3 Trial of the Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration 2-Year Results","volume":"130","author":"Regillo","year":"2023","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108934_bb1015","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1159\/000524096","article-title":"Fluid control in neovascular age-related macular degeneration with brolucizumab: An analysis of the HAWK and HARRIER phase 3 trials","volume":"245","author":"Regillo","year":"2022","journal-title":"Ophthalmologica"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108934_bb1020","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22042179","article-title":"VEGF-independent activation of muller cells by the vitreous from proliferative diabetic retinopathy patients","volume":"22","author":"Rezzola","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108934_bb1025","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2015.07.001","article-title":"Long-term safety with axitinib in previously treated patients with metastatic renal cell carcinoma","volume":"13","author":"Rini","year":"2015","journal-title":"Clinical Genitourinary Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb1030","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1470-2045(19)30735-1","article-title":"Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): A phase 3, multicentre, randomised, controlled, open-label study","volume":"21","author":"Rini","year":"2020","journal-title":"The Lancet Oncology"},{"issue":"10189","key":"10.1016\/j.pharmthera.2025.108934_bb1035","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108934_bb1040","article-title":"Intravenous thrombolytic treatment and endovascular thrombectomy for ischaemic wake-up stroke","volume":"12","author":"Roaldsen","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11\u201312","key":"10.1016\/j.pharmthera.2025.108934_bb1045","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1177\/15459683231207360","article-title":"Mild stroke, serious problems: Limitations in balance and gait capacity and the impact on fall rate, and physical activity","volume":"37","author":"Roelofs","year":"2023","journal-title":"Neurorehabilitation and Neural Repair"},{"key":"10.1016\/j.pharmthera.2025.108934_bb1050","doi-asserted-by":"crossref","first-page":"35660","DOI":"10.1038\/srep35660","article-title":"AKT\/GSK3beta signaling pathway is critically involved in human pluripotent stem cell survival","volume":"6","author":"Romorini","year":"2016","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb1055","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1161\/STROKEAHA.123.043764","article-title":"CNS drug delivery in stroke: Improving therapeutic translation from the bench to the bedside","volume":"55","author":"Ronaldson","year":"2024","journal-title":"Stroke"},{"issue":"14","key":"10.1016\/j.pharmthera.2025.108934_bb1060","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"The New England Journal of Medicine"},{"issue":"20","key":"10.1016\/j.pharmthera.2025.108934_bb1065","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242015200","article-title":"Dysfunctional and dysregulated nitric oxide synthases in cardiovascular disease: Mechanisms and therapeutic potential","volume":"24","author":"Roy","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108934_bb1070","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1080\/02713683.2022.2053166","article-title":"Simultaneous release of aflibercept and dexamethasone from an ocular drug delivery system","volume":"47","author":"Rudeen","year":"2022","journal-title":"Current Eye Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108934_bb1075","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1177\/0271678X20906815","article-title":"Insights into the dual role of angiogenesis following stroke","volume":"40","author":"Rust","year":"2020","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108934_bb1080","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/02611929231181623","article-title":"Fenugreek seed extract regulates human umbilical vein endothelial cell angiogenesis and proliferation via the PI3K\/Akt\/Cyclin D1 pathway","volume":"51","author":"Safarpour","year":"2023","journal-title":"Alternatives to Laboratory Animals"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb1085","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.jjcc.2022.07.003","article-title":"Treatment strategies of acute myocardial infarction: Updates on revascularization, pharmacological therapy, and beyond","volume":"81","author":"Saito","year":"2023","journal-title":"Journal of Cardiology"},{"issue":"14","key":"10.1016\/j.pharmthera.2025.108934_bb1090","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1056\/NEJMoa2214403","article-title":"Trial of endovascular thrombectomy for large ischemic strokes","volume":"388","author":"Sarraj","year":"2023","journal-title":"The New England Journal of Medicine"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108934_bb1095","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"The New England Journal of Medicine"},{"issue":"10266","key":"10.1016\/j.pharmthera.2025.108934_bb1100","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(20)31559-2","article-title":"Retinal vascular occlusions","volume":"396","author":"Scott","year":"2020","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.pharmthera.2025.108934_bb1105","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1001\/jama.2017.4568","article-title":"Effect of bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion: The SCORE2 randomized clinical trial","volume":"317","author":"Scott","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108934_bb1110","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22041843","article-title":"Growth factors VEGF-A(165) and FGF-2 as multifunctional biomolecules governing cell adhesion and proliferation","volume":"22","author":"Sedlar","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb1115","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s10456-010-9174-0","article-title":"Magnetic resonance imaging of brain angiogenesis after stroke","volume":"13","author":"Seevinck","year":"2010","journal-title":"Angiogenesis"},{"issue":"4587","key":"10.1016\/j.pharmthera.2025.108934_bb1120","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1126\/science.6823562","article-title":"Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid","volume":"219","author":"Senger","year":"1983","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.pharmthera.2025.108934_bb1125","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21218118","article-title":"Ischemic heart disease pathophysiology paradigms overview: From plaque activation to microvascular dysfunction","volume":"21","author":"Severino","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2025.108934_bb1130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-981-15-2517-9_1","article-title":"Coronary artery disease: From mechanism to clinical practice","volume":"1177","author":"Shao","year":"2020","journal-title":"Advances in Experimental Medicine and Biology"},{"issue":"46","key":"10.1016\/j.pharmthera.2025.108934_bb1135","article-title":"VEGF inhibition increases expression of HIF-regulated angiogenic genes by the RPE limiting the response of wet AMD eyes to aflibercept","volume":"121","author":"Sharma","year":"2024","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108934_bb1140","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1167\/iovs.64.5.28","article-title":"Mechanisms of acquired resistance to anti-VEGF therapy for neovascular eye diseases","volume":"64","author":"Sharma","year":"2023","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108934_bb1145","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1177\/0271678X18769515","article-title":"PDGFR-beta restores blood-brain barrier functions in a mouse model of focal cerebral ischemia","volume":"39","author":"Shen","year":"2019","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"key":"10.1016\/j.pharmthera.2025.108934_bb1150","doi-asserted-by":"crossref","first-page":"1284981","DOI":"10.3389\/fphys.2023.1284981","article-title":"Research progress on the mechanism of angiogenesis in wound repair and regeneration","volume":"14","author":"Shi","year":"2023","journal-title":"Frontiers in Physiology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108934_bb1155","doi-asserted-by":"crossref","first-page":"e824","DOI":"10.1016\/j.jcjo.2024.01.016","article-title":"Branch retinal vein occlusion treated with anti-VEGF: To switch or not to switch?","volume":"59","author":"Shor","year":"2024","journal-title":"Canadian Journal of Ophthalmology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb1160","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1161\/CIRCRESAHA.121.318174","article-title":"Cerebral Cavernous Malformation: From Mechanism to Therapy","volume":"129","author":"Snellings","year":"2021","journal-title":"Circulation Research"},{"key":"10.1016\/j.pharmthera.2025.108934_bb1165","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.671989","article-title":"Targeted thrombospondin-1 expression in ocular vascular development and neovascularization","volume":"9","author":"Sorenson","year":"2021","journal-title":"Frontiers in Cell and Development Biology"},{"key":"10.1016\/j.pharmthera.2025.108934_bb1170","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113320","article-title":"Alzheimer\u2019s disease and its treatment by different approaches: A review","volume":"216","author":"Srivastava","year":"2021","journal-title":"European Journal of Medicinal Chemistry"},{"issue":"10208","key":"10.1016\/j.pharmthera.2025.108934_bb1175","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(19)31344-3","article-title":"Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): An open-label randomised controlled trial","volume":"394","author":"Stahl","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108934_bb1180","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1001\/jama.2022.10564","article-title":"Effect of intravitreal aflibercept vs laser photocoagulation on treatment success of retinopathy of rrematurity: The FIREFLEYE randomized clinical trial","volume":"328","author":"Stahl","year":"2022","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.pharmthera.2025.108934_bb1185","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1200\/JCO.22.02622","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial","volume":"41","author":"Sternberg","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb1190","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.1038\/s41467-024-46300-0","article-title":"Eph-ephrin signaling couples endothelial cell sorting and arterial specification","volume":"15","author":"Stewen","year":"2024","journal-title":"Nature Communications"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb1195","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1186\/s12885-019-6234-8","article-title":"A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer","volume":"19","author":"Strickler","year":"2019","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb1200","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s13287-020-01881-7","article-title":"HIF-1alpha overexpression in mesenchymal stem cell-derived exosomes mediates cardioprotection in myocardial infarction by enhanced angiogenesis","volume":"11","author":"Sun","year":"2020","journal-title":"Stem Cell Research & Therapy"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108934_bb1205","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1161\/01.RES.0000162099.01268.d1","article-title":"Adenoviral gene transfer of FGF-5 to hibernating myocardium improves function and stimulates myocytes to hypertrophy and reenter the cell cycle","volume":"96","author":"Suzuki","year":"2005","journal-title":"Circulation Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108934_bb1210","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/annonc\/mdx767","article-title":"Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study","volume":"29","author":"Tabernero","year":"2018","journal-title":"Annals of Oncology"},{"issue":"8","key":"10.1016\/j.pharmthera.2025.108934_bb1215","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","article-title":"Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-week results from the BALATON and COMINO trials","volume":"131","author":"Tadayoni","year":"2024","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108934_bb1220","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.jvs.2004.07.012","article-title":"CCR2-\/- knockout mice revascularize normally in response to severe hindlimb ischemia","volume":"40","author":"Tang","year":"2004","journal-title":"Journal of Vascular Surgery"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108934_bb1225","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1073\/pnas.1018925108","article-title":"Coexpression of VEGF and angiopoietin-1 promotes angiogenesis and cardiomyocyte proliferation reduces apoptosis in porcine myocardial infarction (MI) heart","volume":"108","author":"Tao","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb1230","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0197-4580(01)00285-8","article-title":"Increased intrathecal levels of the angiogenic factors VEGF and TGF-beta in Alzheimer's disease and vascular dementia","volume":"23","author":"Tarkowski","year":"2002","journal-title":"Neurobiology of Aging"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb1235","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1038\/s41467-024-46015-2","article-title":"Diagnosis and management of subarachnoid haemorrhage","volume":"15","author":"Thilak","year":"2024","journal-title":"Nature Communications"},{"key":"10.1016\/j.pharmthera.2025.108934_bb1240","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175623","article-title":"ACE2\/ANG-(1-7)\/Mas receptor axis activation prevents inflammation and improves cognitive functions in streptozotocin induced rat model of Alzheimer's disease-like phenotypes","volume":"946","author":"Tiwari","year":"2023","journal-title":"European Journal of Pharmacology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108934_bb1245","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1083\/jcb.201404140","article-title":"ZO-1 controls endothelial adherens junctions, cell-cell tension, angiogenesis, and barrier formation","volume":"208","author":"Tornavaca","year":"2015","journal-title":"The Journal of Cell Biology"},{"key":"10.1016\/j.pharmthera.2025.108934_bb1250","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.49977","article-title":"Coronary arterial development is regulated by a Dll4-Jag1-EphrinB2 signaling cascade","volume":"8","author":"Travisano","year":"2019","journal-title":"Elife"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108934_bb1255","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s10456-021-09796-4","article-title":"Pericyte hypoxia-inducible factor-1 (HIF-1) drives blood-brain barrier disruption and impacts acute ischemic stroke outcome","volume":"24","author":"Tsao","year":"2021","journal-title":"Angiogenesis"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108934_bb1260","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S1474-4422(22)00519-1","article-title":"Thrombolysis for acute ischaemic stroke: Current status and future perspectives","volume":"22","author":"Tsivgoulis","year":"2023","journal-title":"Lancet Neurology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb1265","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/med.21817","article-title":"Mechanisms of neuronal cell death in ischemic stroke and their therapeutic implications","volume":"42","author":"Tuo","year":"2022","journal-title":"Medicinal Research Reviews"},{"key":"10.1016\/j.pharmthera.2025.108934_bb1270","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.100954","article-title":"VEGFR1 signaling in retinal angiogenesis and microinflammation","volume":"84","author":"Uemura","year":"2021","journal-title":"Progress in Retinal and Eye Research"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb1275","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10456-019-09688-8","article-title":"Cancer-associated fibroblast-derived WNT2 increases tumor angiogenesis in colon cancer","volume":"23","author":"Unterleuthner","year":"2020","journal-title":"Angiogenesis"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108934_bb1280","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.oret.2019.12.019","article-title":"Comparing the efficacy of bevacizumab and ranibizumab in patients with retinal vein occlusion: The bevacizumab to ranibizumab in retinal vein occlusions (BRVO) study, a randomized trial","volume":"4","author":"Vader","year":"2020","journal-title":"Ophthalmol Retina"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb1285","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines9020224","article-title":"Anomalous angiogenesis in retina","volume":"9","author":"Vega","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.pharmthera.2025.108934_bb1290","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.addr.2018.09.010","article-title":"Therapeutic strategies for enhancing angiogenesis in wound healing","volume":"146","author":"Veith","year":"2019","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108934_bb1295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011860","article-title":"Quantifying the proteolytic release of extracellular matrix-sequestered VEGF with a computational model","volume":"5","author":"Vempati","year":"2010","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108934_bb1300","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/nrc3914","article-title":"Angiogenesis: A sudden rush of blood to the tumour","volume":"15","author":"Villanueva","year":"2015","journal-title":"Nature Reviews. Cancer"},{"key":"10.1016\/j.pharmthera.2025.108934_bb1305","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/j.ijbiomac.2022.09.129","article-title":"A concise review of VEGF, PDGF, FGF, Notch, angiopoietin, and HGF signalling in tumor angiogenesis with a focus on alternative approaches and future directions","volume":"221","author":"Vimalraj","year":"2022","journal-title":"International Journal of Biological Macromolecules"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb1310","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","article-title":"Macrophages and metabolism in the tumor microenvironment","volume":"30","author":"Vitale","year":"2019","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2025.108934_bb1315","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3389\/fncel.2015.00426","article-title":"Role of TGFbeta signaling in the pathogenesis of Alzheimer\u2019s disease","volume":"9","author":"Von Bernhardi","year":"2015","journal-title":"Frontiers in Cellular Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb1320","doi-asserted-by":"crossref","first-page":"9362","DOI":"10.1038\/s41598-021-88703-9","article-title":"Combined VEGFR and MAPK pathway inhibition in angiosarcoma","volume":"11","author":"Wagner","year":"2021","journal-title":"Scientific Reports"},{"issue":"5","key":"10.1016\/j.pharmthera.2025.108934_bb1325","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/s41583-023-00684-y","article-title":"Shaping the brain vasculature in development and disease in the single-cell era","volume":"24","author":"W\u00e4lchli","year":"2023","journal-title":"Nature Reviews. Neuroscience"},{"issue":"4","key":"10.1016\/j.pharmthera.2025.108934_bb1330","doi-asserted-by":"crossref","first-page":"496","DOI":"10.2174\/1871527314666150821112546","article-title":"Angiopoietin-1 and C16 peptide attenuate vascular and inflammatory responses in experimental allergic encephalomyelitis","volume":"15","author":"Wang","year":"2016","journal-title":"CNS & Neurological Disorders Drug Targets"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108934_bb1335","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1167\/iovs.64.7.13","article-title":"MicroRNA 9 is a regulator of endothelial to mesenchymal transition in diabetic retinopathy","volume":"64","author":"Wang","year":"2023","journal-title":"Investigative Ophthalmology & Visual Science"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108934_bb1340","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/s41401-021-00803-4","article-title":"Catalpol improves impaired neurovascular unit in ischemic stroke rats via enhancing VEGF-PI3K\/AKT and VEGF-MEK1\/2\/ERK1\/2 signaling","volume":"43","author":"Wang","year":"2022","journal-title":"Acta Pharmacologica Sinica"},{"key":"10.1016\/j.pharmthera.2025.108934_bb1345","article-title":"Integrated strategies for targeting arteriogenesis and angiogenesis after stroke","author":"Wang","year":"2024","journal-title":"Translational Stroke Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb1360","doi-asserted-by":"crossref","first-page":"15836","DOI":"10.1038\/s41598-021-95110-7","article-title":"Gastrin mediates cardioprotection through angiogenesis after myocardial infarction by activating the HIF-1alpha\/VEGF signalling pathway","volume":"11","author":"Wang","year":"2021","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2025.108934_bb1365","article-title":"Molecular bases of VEGFR-2-mediated physiological function and pathological role","volume":"8","author":"Wang","year":"2020","journal-title":"Frontiers in Cell and Development Biology"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108934_bb1370","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.jjcc.2021.10.014","article-title":"EphrinB2-RhoA upregulation attenuates sympathetic hyperinnervation and decreases the incidence of ventricular arrhythmia after myocardial infarction","volume":"79","author":"Wang","year":"2022","journal-title":"Journal of Cardiology"},{"key":"10.1016\/j.pharmthera.2025.108934_bb1375","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117113","article-title":"The natural compound sinometumine E derived from Corydalis decumbens promotes angiogenesis by regulating HIF-1\/ VEGF pathway in vivo and in vitro","volume":"178","author":"Wang","year":"2024","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108934_bb1380","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: Two-year results from a comparative effectiveness randomized clinical trial","volume":"123","author":"Wells","year":"2016","journal-title":"Ophthalmology"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108934_bb1385","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/mabi.201300128","article-title":"Collagen-polymer guidance of vessel network formation and stabilization by endothelial colony forming cells in vitro","volume":"13","author":"Whittington","year":"2013","journal-title":"Macromolecular Bioscience"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108934_bb1390","article-title":"Optical coherence tomography angiography as a diagnostic tool for diabetic retinopathy","volume":"14","author":"Wijesingha","year":"2024","journal-title":"Diagnostics (Basel)"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108934_bb1395","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1089\/wound.2018.0796","article-title":"Vascular endothelial growth factor and cutaneous scarring","volume":"8","author":"Wilgus","year":"2019","journal-title":"Advance Wound Care (New Rochelle)"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108934_bb1400","doi-asserted-by":"crossref","DOI":"10.1172\/JCI178296","article-title":"Complement regulation in the eye: Implications for age-related macular degeneration","volume":"134","author":"Wilke","year":"2024","journal-title":"The Journal of Clinical Investigation"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb1405","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ccell.2014.10.015","article-title":"Dual-action combination therapy enhances angiogenesis while reducing tumor growth and spread","volume":"27","author":"Wong","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2025.108934_bb1410","doi-asserted-by":"crossref","first-page":"16012","DOI":"10.1038\/nrdp.2016.12","article-title":"Diabetic retinopathy","volume":"2","author":"Wong","year":"2016","journal-title":"Nature Reviews. Disease Primers"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108934_bb1415","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","article-title":"Faricimab treat-and-extend for diabetic macular edema: Two-year results from the randomized phase 3 YOSEMITE and RHINE trials","volume":"131","author":"Wong","year":"2024","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb1420","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41392-023-01481-w","article-title":"The blood-brain barrier: Structure, regulation, and drug delivery","volume":"8","author":"Wu","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"7","key":"10.1016\/j.pharmthera.2025.108934_bb1425","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1136\/bjophthalmol-2020-318026","article-title":"Comparison of clinical outcomes of conbercept versus ranibizumab treatment for retinopathy of prematurity: A multicentral prospective randomised controlled trial","volume":"106","author":"Wu","year":"2022","journal-title":"The British Journal of Ophthalmology"},{"key":"10.1016\/j.pharmthera.2025.108934_bb1430","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.102219","article-title":"A new FGF1 variant protects against adriamycin-induced cardiotoxicity via modulating p53 activity","volume":"49","author":"Xiao","year":"2022","journal-title":"Redox Biology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb1435","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41467-021-27944-8","article-title":"HIF-1 interacts with TRIM28 and DNA-PK to release paused RNA polymerase II and activate target gene transcription in response to hypoxia","volume":"13","author":"Yang","year":"2022","journal-title":"Nature Communications"},{"issue":"12","key":"10.1016\/j.pharmthera.2025.108934_bb1440","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.2174\/1570159X18666200720173316","article-title":"Angiogenesis and blood-brain barrier permeability in vascular remodeling after stroke","volume":"18","author":"Yang","year":"2020","journal-title":"Current Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2025.108934_bb1445","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: Current advances and future directions","volume":"21","author":"Yi","year":"2022","journal-title":"Molecular Cancer"},{"issue":"3","key":"10.1016\/j.pharmthera.2025.108934_bb1450","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ophtha.2014.09.024","article-title":"Improvement in vision-related function with intravitreal aflibercept: Data from phase 3 studies in wet age-related macular degeneration","volume":"122","author":"Yuzawa","year":"2015","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.pharmthera.2025.108934_bb1455","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1021\/acscentsci.3c00377","article-title":"A triple-targeted rutin-based self-assembled delivery vector for treating ischemic stroke by vascular normalization and anti-inflammation via ACE2\/Ang1-7 signaling","volume":"9","author":"Zhao","year":"2023","journal-title":"ACS Central Science"},{"issue":"2","key":"10.1016\/j.pharmthera.2025.108934_bb1460","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2021.5070","article-title":"Neuronal injuries in cerebral infarction and ischemic stroke: From mechanisms to treatment (review)","volume":"49","author":"Zhao","year":"2022","journal-title":"International Journal of Molecular Medicine"},{"issue":"14","key":"10.1016\/j.pharmthera.2025.108934_bb1465","doi-asserted-by":"crossref","first-page":"13506","DOI":"10.1074\/jbc.M310164200","article-title":"PI3K\/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-independent degradation","volume":"279","author":"Zhou","year":"2004","journal-title":"The Journal of Biological Chemistry"},{"issue":"13","key":"10.1016\/j.pharmthera.2025.108934_bb1470","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.7150\/thno.98467","article-title":"Targeted degradation of VEGF with bispecific aptamer-based LYTACs ameliorates pathological retinal angiogenesis","volume":"14","author":"Zhou","year":"2024","journal-title":"Theranostics"},{"issue":"9","key":"10.1016\/j.pharmthera.2025.108934_bb1475","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ccell.2021.07.005","article-title":"Bevacizumab plus erlotinib in chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study","volume":"39","author":"Zhou","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharmthera.2025.108934_bb1480","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2023.114532","article-title":"MCPIP-1 knockdown enhances endothelial colony-forming cell angiogenesis via the TFRC\/AKT\/mTOR signaling pathway in the ischemic penumbra of MCAO mice","volume":"369","author":"Zou","year":"2023","journal-title":"Experimental Neurology"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725825001469?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725825001469?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T11:02:49Z","timestamp":1766055769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725825001469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":294,"alternative-id":["S0163725825001469"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108934","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Crosstalk between anti-angiogenic and pro-angiogenic pathways in disease: Mechanisms and therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2025.108934","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108934"}}